Assignee
DICERNA PHARMACEUTICALS INC
US·96 granted patents·44 pending applications·499 citations·filing 2009–2025
Top patents by PatentIndex Score
140 records- 0199US8927705B2Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2012·Granted Jan 6, 2015·83 cites·46 claims
- 0298US8349809B2Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2010·Granted Jan 8, 2013·162 cites·102 claims
- 0396US10370655B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2016·Granted Aug 6, 2019·14 cites·22 claims
- 0496US10144725B2Amine cationic lipids and uses thereofDICERNA PHARMACEUTICALS INC·Filed 2017·Granted Dec 4, 2018·21 cites·25 claims
- 0596US9458457B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Oct 4, 2016·19 cites·52 claims
- 0695US11359198B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Jun 14, 2022·2 cites·23 claims
- 0794US10870849B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2014·Granted Dec 22, 2020·7 cites·63 claims
- 0894US10131912B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2014·Granted Nov 20, 2018·15 cites·8 claims
- 0994US8372816B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2010·Granted Feb 12, 2013·12 cites·57 claims
- 1093US12077756B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2022·Granted Sep 3, 2024·1 cites·22 claims
- 1193US11661604B2Methods and compositions for inhibiting expression of LDHADICERNA PHARMACEUTICALS INC·Filed 2020·Granted May 30, 2023·3 cites·20 claims
- 1293US10036017B2Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2016·Granted Jul 31, 2018·5 cites·24 claims
- 1393US9701966B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Jul 11, 2017·12 cites·68 claims
- 1492US11597929B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Mar 7, 2023·1 cites·20 claims
- 1592US11052104B2Methods for treating hepatitis B infectionDICERNA PHARMACEUTICALS INC·Filed 2020·Granted Jul 6, 2021·3 cites·20 claims
- 1692US10837013B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2014·Granted Nov 17, 2020·5 cites·63 claims
- 1792US10351854B2Therapeutic inhibition of lactate dehydrogenase and agents thereforDICERNA PHARMACEUTICALS INC·Filed 2015·Granted Jul 16, 2019·9 cites·34 claims
- 1892US10150965B2Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Dec 11, 2018·6 cites·24 claims
- 1992US9828606B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2017·Granted Nov 28, 2017·7 cites·38 claims
- 2092US8815825B2Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2012·Granted Aug 26, 2014·12 cites·45 claims
- 2191US11414664B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Aug 16, 2022·1 cites·20 claims
- 2291US11408003B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Aug 9, 2022·1 cites·23 claims
- 2391US11060093B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2019·Granted Jul 13, 2021·2 cites·20 claims
- 2491US10752899B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2017·Granted Aug 25, 2020·3 cites·31 claims
- 2591US10676742B2Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Jun 9, 2020·3 cites·30 claims
- 2691US9200284B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2013·Granted Dec 1, 2015·5 cites·53 claims
- 2790US11053502B1Therapeutic inhibition of lactate dehydrogenase and agents thereforDICERNA PHARMACEUTICALS INC·Filed 2020·Granted Jul 6, 2021·2 cites·30 claims
- 2890US10738311B2Therapeutic inhibition of lactate dehydrogenase and agents thereforDICERNA PHARMACEUTICALS INC·Filed 2019·Granted Aug 11, 2020·3 cites·39 claims
- 2989US11773390B2Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2020·Granted Oct 3, 2023·1 cites·20 claims
- 3088US11634713B2Extended dicer substrate agents and methods for the specific inhibition of gene expressionDICERNA PHARMACEUTICALS INC·Filed 2020·Granted Apr 25, 2023·1 cites·32 claims
- 3188US10954517B2Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Mar 23, 2021·2 cites·20 claims
- 3288US9809819B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Nov 7, 2017·6 cites·26 claims
- 3388US8927515B2Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2012·Granted Jan 6, 2015·9 cites·42 claims
- 3487US12252691B2Compositions and methods for inhibiting LPA expressionDICERNA PHARMACEUTICALS INC·Filed 2024·Granted Mar 18, 2025·0 cites·4 claims
- 3587US11447777B2Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2020·Granted Sep 20, 2022·1 cites·27 claims
- 3687US10799524B2Methods for treating hepatitis B infectionDICERNA PHARMACEUTICALS INC·Filed 2020·Granted Oct 13, 2020·2 cites·21 claims
- 3787US10675295B2Compositions and methods for inhibiting HMGB1 expressionDICERNA PHARMACEUTICALS INC·Filed 2018·Granted Jun 9, 2020·5 cites·20 claims
- 3887US10435692B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2017·Granted Oct 8, 2019·3 cites·20 claims
- 3986US11414659B24'-phosphate analogs and oligonucleotides comprising the sameDICERNA PHARMACEUTICALS INC·Filed 2017·Granted Aug 16, 2022·3 cites·44 claims
- 4086US11273173B2Methods for treating hepatitis B infectionDICERNA PHARMACEUTICALS INC·Filed 2021·Granted Mar 15, 2022·1 cites·30 claims
- 4186US9732347B2Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2014·Granted Aug 15, 2017·6 cites·38 claims
- 4285US10689647B2Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2016·Granted Jun 23, 2020·2 cites·32 claims
- 4385US10612023B2Methods and compositions for the specific inhibition of β-catenin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Apr 7, 2020·1 cites·21 claims
- 4485US10487330B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2019·Granted Nov 26, 2019·2 cites·30 claims
- 4585US10465195B2Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2019·Granted Nov 5, 2019·2 cites·28 claims
- 4685US9217146B2Phase changing formulations of nucleic acid payloadsDICERNA PHARMACEUTICALS INC·Filed 2013·Granted Dec 22, 2015·4 cites·20 claims
- 4784US11851658B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2022·Granted Dec 26, 2023·0 cites·17 claims
- 4883US11912996B2Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNADICERNA PHARMACEUTICALS INC·Filed 2022·Granted Feb 27, 2024·0 cites·24 claims
- 4983US9549983B2Amine cationic lipids and uses thereofDICERNA PHARMACEUTICALS INC·Filed 2014·Granted Jan 24, 2017·4 cites·31 claims
- 5082US11052105B2Methods for treating hepatitis B infectionDICERNA PHARMACEUTICALS INC·Filed 2020·Granted Jul 6, 2021·1 cites·27 claims
Showing the top 50 of 140 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when DICERNA PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →